A New Category of Affordable Medicine
Biosimilars are highly similar versions of already-approved biologic drugs — complex medications manufactured from living cells — that offer a path to lower-cost treatment once the original biologic patent expires. Unlike traditional generic drugs, which are exact chemical copies of simple small-molecule medications, biosimilars cannot be identical to their reference biologic because biologics are too structurally complex to replicate perfectly, requiring a different regulatory framework to establish equivalence.
Similar, Not Identical, and Why That Is Fine
Biosimilars undergo extensive testing to demonstrate no clinically meaningful differences from the reference biologic in safety, purity, and effectiveness, even though minor structural variations are inevitable given how biologics are manufactured in living systems. This rigorous approval standard means biosimilars are expected to work the same way clinically as the original biologic, offering genuine therapeutic equivalence rather than a lesser alternative, despite the naming distinction from generics.
The Cost Impact
Because biologics rank among the most expensive medications, often costing patients and health systems tens of thousands of dollars annually, biosimilar competition has produced substantial savings as more biosimilars reach market for conditions like autoimmune disease and cancer. Wider adoption of biosimilars where clinically appropriate represents one of the most significant levers available for reducing pharmaceutical spending without compromising treatment quality. Facilities can source pharmacy supplies and lab supplies from our catalog.
